Lupin Of India To Expand Generic Filings For Chronic Diseases In U.S.
This article was originally published in PharmAsia News
Executive SummaryIndia's Lupin is increasing funding for its intellectual-property division so it can file scores of petitions for the U.S. generics market
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.